Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging.


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
10 2020
Historique:
received: 19 02 2018
accepted: 10 08 2018
pubmed: 23 8 2018
medline: 23 11 2021
entrez: 23 8 2018
Statut: ppublish

Résumé

In patients undergoing regadenoson SPECT myocardial perfusion imaging (MPI), the prognostic value of ischemic ST-segment depression (ST↓) and the optimal ST↓ threshold have not been studied. A retrospective cohort study of consecutive patients referred for regadenoson stress MPI was conducted. Patients with uninterpretable ECG were excluded. Two diagnostic thresholds of horizontal or downsloping ST↓ were studied, ≥ 0.5 mm and ≥ 1.0 mm. The primary endpoint was the composite major adverse cardiac events (MACE) of cardiac death, myocardial infarction, or coronary revascularization. Among 8615 subjects (mean age 62 ± 13 years; 55% women), 89 (1.0%) had ST↓ ≥ 1.0 mm and 133 (1.5%) had ST↓ ≥ 0.5 mm. Regadenoson-induced ST↓ was more common in women (P < .001). Mean follow-up was 2.5 ± 2.2 years. After multivariate adjustment, ST↓ ≥ 1.0 mm was associated with a non-significant increase in MACE risk (P = .069), irrespective to whether MPI was abnormal (P = .162) or normal (P = .214). Ischemic ST↓ ≥ 0.5 mm was independently associated with MACE in the entire cohort (HR 2.14; CI 1.38-3.32; P = .001), whether MPI is normal (HR 2.07; CI 1.07-4.04; P = .032) or abnormal (HR 2.24; CI 1.23-4.00; P = .007), after adjusting for clinical and imaging covariates. An ST↓ threshold of ≥ 0.5 mm provided greater incremental prognostic value beyond clinical and imaging parameters (Δχ Regadenoson-induced ischemic ST↓ is more common in women and it provides a modest independent prognostic value beyond MPI and clinical parameters. ST↓ ≥ 0.5 mm is a better threshold than ≥ 1.0 mm to define ECG evidence for regadenoson-induced myocardial ischemia.

Sections du résumé

BACKGROUND
In patients undergoing regadenoson SPECT myocardial perfusion imaging (MPI), the prognostic value of ischemic ST-segment depression (ST↓) and the optimal ST↓ threshold have not been studied.
METHODS
A retrospective cohort study of consecutive patients referred for regadenoson stress MPI was conducted. Patients with uninterpretable ECG were excluded. Two diagnostic thresholds of horizontal or downsloping ST↓ were studied, ≥ 0.5 mm and ≥ 1.0 mm. The primary endpoint was the composite major adverse cardiac events (MACE) of cardiac death, myocardial infarction, or coronary revascularization.
RESULTS
Among 8615 subjects (mean age 62 ± 13 years; 55% women), 89 (1.0%) had ST↓ ≥ 1.0 mm and 133 (1.5%) had ST↓ ≥ 0.5 mm. Regadenoson-induced ST↓ was more common in women (P < .001). Mean follow-up was 2.5 ± 2.2 years. After multivariate adjustment, ST↓ ≥ 1.0 mm was associated with a non-significant increase in MACE risk (P = .069), irrespective to whether MPI was abnormal (P = .162) or normal (P = .214). Ischemic ST↓ ≥ 0.5 mm was independently associated with MACE in the entire cohort (HR 2.14; CI 1.38-3.32; P = .001), whether MPI is normal (HR 2.07; CI 1.07-4.04; P = .032) or abnormal (HR 2.24; CI 1.23-4.00; P = .007), after adjusting for clinical and imaging covariates. An ST↓ threshold of ≥ 0.5 mm provided greater incremental prognostic value beyond clinical and imaging parameters (Δχ
CONCLUSION
Regadenoson-induced ischemic ST↓ is more common in women and it provides a modest independent prognostic value beyond MPI and clinical parameters. ST↓ ≥ 0.5 mm is a better threshold than ≥ 1.0 mm to define ECG evidence for regadenoson-induced myocardial ischemia.

Identifiants

pubmed: 30132187
doi: 10.1007/s12350-018-1415-4
pii: 10.1007/s12350-018-1415-4
doi:

Substances chimiques

Adenosine A2 Receptor Agonists 0
Purines 0
Pyrazoles 0
regadenoson 2XLN4Y044H

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1521-1532

Commentaires et corrections

Type : CommentIn

Auteurs

Rami Doukky (R)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA. rdoukky@cookcountyhhs.org.
Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. rdoukky@cookcountyhhs.org.
Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA. rdoukky@cookcountyhhs.org.
Department of Medicine, Rush University Medical Center, Chicago, IL, USA. rdoukky@cookcountyhhs.org.

Abiy Nigatu (A)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA.

Rozi Khan (R)

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Chiedozie Anokwute (C)

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Ibtihaj Fughhi (I)

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Ali Ayoub (A)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA.

Fady Iskander (F)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA.

Mina Iskander (M)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA.

Snigdha Kola (S)

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Mark Sahyouni (M)

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Kelly Karavolos (K)

Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA.

Bala N Hota (BN)

Department of Medicine, Rush University Medical Center, Chicago, IL, USA.

Javier Gomez (J)

Division of Cardiology, Cook County Health and Hospitals System, 1901 W. Harrison St., Chicago, IL, 60612, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH